progression-free survival rates

There was no difference in disease response or progression-free survival rates between patients receiving the drug for multiple myeloma and the control group.

Reported 5-year progression-free survival rates have ranged from approximately 35% to 60% for children receiving platinum-based chemotherapy for optic pathway gliomas,[5,17] but most patients ultimately require further treatment.

This trial compared the outcome of gemcitabine/erlotinib to gemcitabine/placebo, and demonstrated improved survival rates, improved tumor response and improved progression-free survival rates.